Juno Therapeutics appoints executive vice president
Prior to her tenure at Roche, which included three years as Head of Global Biometrics and Development Innovation, Dr. Sanders worked in a number of senior leadership roles at Genentech, where her responsibilities included biostatistics, epidemiology, health economics and outcomes research, data management, medical writing, information technology, and biosample management.
In her 23 years with Genentech and Roche, Dr. Sanders oversaw diverse aspects of early-to-late development programs spanning the therapeutic areas of oncology, immunology, pulmonary, rheumatology, respiratory, neurology, ophthalmology, cardiovascular, inflammatory bowel disease, endocrinology, and infectious disease.
Dr. Sanders was instrumental in the development and submission of Rituxan, Herceptin and its companion diagnostic Herceptest, and Avastin. She also led the planning and execution for the development of other products at both companies.
Dr. Sanders holds bachelor’s and master’s degrees in statistics from the University of the Philippines, and received a master’s degree and doctorate in statistics from the Wharton School at the University of Pennsylvania. ■
LATEST MOVES FROM Washington
- Juno Therapeutics appoints Rupert Vessey to board
- HomeStreet appoints Mark R. Ruh as interim CFO
- Avalara appoints Tony Susak as general manager
- Red Lion Hotels adds two to board
- Expedia appoints Chelsea Clinton to board
More inside POST